At the end of January 2026, AstraZeneca, a Swedish-British pharmaceutical and biotechnology company, announced its re-entry into China's pharmaceutical market with a $15 billion investment over the ...

Orphan status in the U.S. can confer clinical-trial tax credits, user-fee exemptions, and up to seven years of post-approval market exclusivity for rare-disease programs. As a deuterated form of ...

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.